Keywords: 2,4-D; 2,4-dichlorophenoxyacetic acid; BR; breaker; DAA; days after anthesis; DAO; DIOXYGENASE FOR AUXIN OXIDATION; FB; flower bud; Fl; flower; GH3; GRETCHEN HAGEN 3; GUS; β-glucuronidase; HPLC/MS/MS; high performance liquid chromatography coupled with a
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Grafted cucumber; Transcriptome; Flavor quality; Sugar; α-Linolenic acid metabolism; G1; fruit obtained from cucumber seedlings grafted onto figleaf gourd (Cucurbita ficifolia) rootstock; G2; fruit obtained from cucumber seedlings grafted onto 'Weishen
Keywords: DAA; days after anthesis; ELISA; enzyme-linked immunosorbent assay; SUT; sucrose transporter; Fv/Fm; maximumâfluorescence quantumâyieldâofâphotosystemâII; HTS; high temperature susceptible mutant; NIPP; Nipponbare; NSC; nonstructural carbohydrat
Keywords: ALT; Alanine Aminotransferase; AST; Aspartate Aminotransferase; BMT; Bone Marrow Transplantation; DAA; Direct-Acting Antiviral; DILI; Drug Induced Liver Injury; GVHD; Graft Versus Host Disease; HAI; Hepatic Activity Index; HCV; Hepatitis C Virus; MRI; Mag
Keywords: anti-infectives; bioavailability; clinical pharmacokinetics; formulation; oral absorption; pharmacokinetics; HCV; hepatitis C virus; GT; genotype; DAA; direct-acting antiviral; RBV; ribavirin; GLE; glecaprevir; PIB; pibrentasvir; Cmax; maximum plasma conc
Keywords: Amylopectin; Amylose; Biotechnology; Metabolism; Seed; Starch synthesis; Sucrose transport; Wheat; ABA; abscisic acid; ADP; adenosine diphosphate; AGPase; ADP-glucose pyrophosphorylase; CWINV; cell wall invertase; DAA; days after anthesis; DBE; debranchin
Keywords: BS; berry shrivel; ICP-MS; inductively coupled plasma mass spectrometry; qPCR; quantitative polymerase chain reaction; SAD; sugar accumulation disorder; SOUR; suppression of uniform ripening; NRQ; normalized relative quantities; DAA; days after anthesis;
Keywords: Gluten proteins; Polymerisation; Breadmaking quality; Artificial drying; ADG; artificially dried grain; DAA; days after anthesis; FDG; freeze-dried grain; GMP; glutenin macropolymer; HMW-GS; high molecular weight-glutenin subunits; LMW-GS; low molecular w
Keywords: ACAT; Aged Care Assessment Team; ADE; adverse drug event; BZD; benzodiazepine; DAA; dose administration aid; DDD; defined daily dose; GP; general medical practitioner; HYVET; Hypertension in the Very Elderly Trial; MAC; Medication Advisory Committee; PART
Keywords: DAA; days after anthesis; SuSy; sucrose synthetase; SPS; sucrose phosphate synthase; Potassium; Cottonseed; Carbohydrate metabolism;
Keywords: AA; Amino acid; DAA; Dispensable amino acid; IAA; Indispensable amino acid; ARG; Arginine in experimental diet; Arg; Arginine; GLN; Glutamine in experimental diet; Gln; Glutamine; SEC; Superoxide anion extracellular; SIC; Superoxide anion intracellular; N
Keywords: Hip; Total hip replacement; Direct anterior hip; DA; DAA; Total hip arthroplasty; Joint replacement;
Keywords: UNOS/OPTN; Database; Liver Cancer; LT; BMI; body mass index; CI; confidence interval; DAA; direct antiviral agent; HCC; hepatocellular carcinoma; HBV; hepatitis B virus; HCV; hepatitis C virus; HR; hazard ratio; LT; liver transplantation; MELD; Model for
Keywords: BNab; broadly neutralising antibody; CTL; cytotoxic lymphocyte; DAA; direct-acting antiviral; HBV; hepatitis B virus; HCV; hepatitis C virus; HIV; human immunodeficiency virus; NGS; next generation sequencing; SGA; single genome amplification; SNP; single
Keywords: Cost Effectiveness; Budget Impact; Public Health; Health Care Expenses; CEA; cost-effectiveness analysis; CHEERS; The Consolidated Health Economic Evaluation Reporting Standards; DAA; direct-acting antiviral; HCV; hepatitis C virus; ICER; incremental cost
Keywords: HCV; hepatitis C virus; RNA; Ribonucleic Acid; RT-PCR; Reverse-transcriptase Polymerase Chain Reaction; DNA; Deoxyribonucleic Acid; IFN; interferon; RBV; ribavirin; PEG; pegylated; DAA; direct-acting antiviral; SVR; sustained viral response; Hepatitis C;
Keywords: Phaseolus vulgaris; Bean seed development; Nutrient restriction; SnRK1; DAA; days after anthesis; FSSA; final stage in seed abortion;
Keywords: ANRS; (France REcherche Nord & sud Sida-vih Hépatites); HCV; hepatitis C virus; RNA; ribonucleic Acid; DAA; direct-acting antivirals; HCC; hepatocellular carcinoma; SVR; sustained virological response; RR; relative risk; INF; interferon; US; ultra-sound;
Keywords: BZD; benzodiazepine; DAA; dopaminergic agonists; DBS; deep brain stimulation; GSI; general symptomatic index; HAMA; Hamilton anxiety rating scale; ICD; impulse control disorder; IGT; Iowa Gambling Task; l-DOPA; l-3,4-dihydroxyphenylalanine; LEDD; l-DOPA e
Keywords: DAA; day after anthesis; WUE; water-use efficiency; SET; seasonal evapotranspiration; ÎS; apparent change of soil water storage; Pn; photosynthetic rate; NCP; North China Plain; Winter wheat; Tillage; Grain yield; Water use; Dry matter remobilisation;
Keywords: Avena sativa L.; Total antioxidant capacity; Soluble phenolic content; Grain development; ABTS; 2,2â²-azinobis(3-ethylbenzothiazoline-6-sulfonic acid); daa; days after anthesis; SPC; soluble phenolic content; TAC; total antioxidant capacity; Trolox; 6-hy
Keywords: AIDS; acquired immunodeficiency syndrome; ALT; alanine aminotransferase; ANRS; French Research Agency on HIV/AIDS and viral hepatitis; ART; antiretroviral treatment; AST; aspartate aminotransferase; DAA; direct-acting antiviral agent; GAVI; Global Allianc
Keywords: Durum wheat; Glutenin; Polymeric protein; Protein composition; Size-exclusion HPLC; Wheat quality; DAA; days after anthesis; DM; dry mass; EPP; total SDS-extractable polymeric proteins; GWM; mass of water per grain; SD; sowing date; SDS; sodium dodecyl su
Keywords: Trusted computing; Remote attestation; DAA; Delegation; Cross trusted domain
Keywords: Cryoglobulins; Insulin Resistance; Cardiovascular Risk; Fatigue; Health-Related Quality of Life; anti-HCV; antibodies to hepatitis C virus; CI; confidence interval; CNS; central nervous system; DAA; direct-acting antiviral; HBV; hepatitis B virus; HCC; he
Keywords: Anthocyanin composition; Purple kidney bean; Molecular regulation; HPLC-ESI-MS/MS; DAA; days after anthesis; FW; fresh weight; PAL; phenylalanine ammonia-lyase; C4H; cinnamate 4-hydroxylase; CHS; chalcone synthase; CHI; chalcone isomerase; F3H; flavone 3-
Keywords: DAA; direct-acting antiviral; HCV; hepatitis C virus; SVR; sustained virologic response; PR; peginterferon plus ribavirin; EPO; erythropoietin; BMI; body mass index; Hb; hemoglobin; ROC; receiver-operator characteristic; CI; confidence interval; OR; odds
Keywords: ABA; abscisic acid; AGPase; adenosine 5â² diphosphate glucose pyrophosphorylase; CTAB; hexadecyltrimethylammonium bromide; DAA; days after anthesis; DWC; dual-wavelength colorimetric; GAPDH; glyceraldehyde-phosphate dehydrogenase; GBSS I; granule-bound s
Keywords: Echocardiography; Vascular ring; Fetal anomalies; DAA; Double aortic arch; RAA; Right aortic arch; VSD; Ventricular septal defect;
Keywords: DAA; NS3/4A Protease Inhibitor; Nucleoside/Nucleotide; Non-nucleoside; DAA; direct-acting antiviral agent; DCV; daclatasvir; HCV; hepatitis C virus; HTA; host-targeted antiviral agent; IFN; interferon; ISG; interferon-stimulated gene; NI; nucleoside inhib
Keywords: BMI; Body mass index; DAA; Diabetes-associated autoantibody; DKA; Diabetic ketoacidosis; HbA1c; Hemoglobin A1c; PDC; Pediatric Diabetes Consortium; SES; Socioeconomic status; T1D; Type 1 diabetes;
Keywords: BBCH; Bundesanstalt, Bundessortenamt and Chemical industry scale; BR; bud rot; DAA; days after anthesis; DOBI; deterioration of bleachability index; FFA; free fatty acids; KB; Kernel to bunch; LW; lethal wilt; MBW; mean bunch weight; MF; mesocarp to fruit
Keywords: DENV; dengue virus; WNV; West Nile virus; YFV; yellow fever virus; TBEV; tick-borne encephalitis virus; HCV; hepatitis C virus; WEEV; Western equine encephalitis virus; VSV; vesicular stomatitis virus; HBV; hepatitis B virus; HIV; human immunodeficiency v
12 weeks ombitasvir/paritaprevir-ritonavirâ¯+â¯ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis
Keywords: DAA; Genotype 4; Paritaprevir; RAS;
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major
Keywords: DAA; Direct Acting Antiviral; DCV; Daclatasvir; ETR; End of Treatment Response; HCV; Hepatitis C Virus; PegINF-α; Pegylated Interferon-α; RBV; Ribavirin; RVR; Rapid Virological Response; SOF; Sofosbuvir; SVR12; Sustained Virological Response Post-treatm
Hepatitis C mixed cryoglobulinemia with undetectable viral load: A case series
Keywords: hepatitis C mixed cryoglobulinemia vasculitis; undetectable viral load; DAA; direct-acting antiretrovirals; HCV; hepatitis C virus; LCV; leukocytoclastic vasculitis;
Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function
Keywords: HCV; Extrahepatic manifestation; Direct-acting antivirals; DAA; Endothelial function; Vascular inflammation;
HSP70 Copurifies with Zika Virus Particles
Keywords: AHI; allosteric HSP70 inhibitor; DAA; direct acting antiviral; DGC; density-gradient centrifugation; HCV; hepatitis C virus; HSP; heat shock protein; MOI; multiplicity of infection; MTase; methyltransferase; NBD; nucleotide binding domain; NCR; non-coding
Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients
Keywords: Pharmacogenetics; SNP; DAA; Calcitriol; Chronic hepatitis C; Therapeutic drug monitoring;
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Keywords: Sofosbuvir; Daclatasvir; Simeprevir; DAA; Sustained virological response;
Closure time of ductus arteriosus after birth based on survival analysis
Keywords: DA; ductus arteriosus; PDA; patent ductus arteriosus; PGE2; prostaglandins E2 (PGE2); DAA; congenital ductus arteriosus aneurysm; echo; echocardiography; NICU; neonatal intensive care unit; Ductus arteriosus; Interval censoring; Normal neonates; Closing t
Age related depth profiles of human Stratum Corneum barrier-related molecular parameters by confocal Raman microscopy in vivo
Keywords: SC; stratum corneum; CRM; confocal Raman microscopy; FFA; free fatty acid; TEWL; Transepidermal Waterloss; HWN; high wavenumber; ICL; intercellular lipid; AUC; area under the curve; DA; single donor-single acceptor; DDAA; double donor-double acceptor;
Hepatitis C virus infection spontaneous clearance: Has it been underestimated?
Keywords: HCV; hepatitis C virus; PWID; people who inject drugs; RNA; ribonucleic acid; Ab; HCV antibody; SM; supplementary material; EDHS; Egypt Demographic and Health Surveys; NHANES; National Health and Nutrition Examination Surveys; CI; Confidence Interval; UI;
Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis
Keywords: DAA; Direct Acting Anti-viral; FIB 4; Fibrosis Score 4; HCV; Hepatitis C Virus; IL-18; Interleukin 18; INF; Interferon; NS; Non-Structural; PCR; Polymerase Chain Reaction; RFLP; Restriction Fragment Length Polymorphism; RNA; Ribonucleic Acid; SNPs; Single
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective
Keywords: chronic kidney disease; DAA; elbasvir; grazoprevir; HCV; hemodialysis;
Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada
Keywords: Hepatitis C; Daa; Injection drug use; Primary care; Opioid agonist therapy;
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Keywords: Direct-acting Antiviral; DAA; Short-duration; Pangenotypic; ALT; alanine aminotransferase; CI; confidence interval; DAA; direct-acting antiviral; G/P; glecaprevir/pibrentasvir; HCV; hepatitis C virus; IFN; interferon; ITT; intention-to-treat; LLOQ; lower
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure
Keywords: BVAS v3; Complication; Immunoglobulin; SVR; ACC; asymptomatic circulating cryoglobulin; BVAS.v3; Birmingham Vasculitis Activity Score version 3; CC; circulating cryoglobulin; CH50; total hemolytic complement fraction; CV; cryoglobulinemic vasculitis; DAA;
Interferon-free direct-acting antiviral therapy for acute hepatitis C virus infection in HIV-infected individuals: A literature review
Keywords: Acute HCV; DAA; HIV; Interferon-sparing;